Welcome to our dedicated page for Quantum-Si Incorporated SEC filings (Ticker: QSI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles U.S. SEC filings for Quantum-Si Incorporated (Nasdaq: QSI), a proteomics technology and life sciences company focused on single-molecule protein analysis and Next-Generation Protein Sequencing. Here, investors can review how Quantum-Si reports its financial performance, capital structure, and material corporate events in official regulatory documents.
Quantum-Si’s periodic reports, such as its quarterly results furnished via Form 8-K, provide detail on product and service revenue, cost of revenue, research and development spending, selling, general and administrative expenses, and items like lease termination or legal settlement expenses. These filings also include condensed consolidated balance sheets and statements of operations, along with non-GAAP metrics such as adjusted total operating expenses and adjusted EBITDA, together with reconciliations to GAAP measures.
Capital markets and financing activities are documented in Forms 8-K and related registration statements. Examples include a registered direct offering of Class A common stock and pre-funded warrants, an at-the-market Sales Agreement for Class A common stock, and the termination of a prior equity distribution agreement. Filings describe intended uses of proceeds, such as funding the Proteus platform development, commercialization, manufacturing development, research and development, and general corporate purposes.
Other material agreements and corporate actions, including lease terminations, settlement and mutual release agreements, and inducement equity awards under the 2023 Inducement Equity Incentive Plan, are also reported in Quantum-Si’s SEC filings. Stock Titan’s interface adds AI-powered summaries that highlight key terms, financial impacts, and timelines from these documents, helping readers quickly understand complex agreements, capital raises, and operating decisions without reading every line of each filing.
Quantum-Si Inc director Charles R. Kummeth reported an open-market purchase of 500,000 shares of Class A common stock on March 5, 2026. The weighted average purchase price was $0.9196 per share, with individual trades executed between $0.8906 and $0.9735 per share. Following this transaction, he directly holds 855,000 shares of Quantum-Si common stock.
Quantum-Si Inc director Paula Dowdy purchased Class A common stock in an open-market transaction. On March 5, 2026, she bought 109,890 shares at a weighted average price of $0.9505 per share, and held 269,107 shares directly after the trade.
The footnote explains that the $0.9505 figure is a weighted average, with actual purchase prices ranging from $0.9051 to $0.9730 per share. Detailed price breakdowns are available upon request from regulators, the company, or its security holders.
Quantum-Si Incorporated is an early-stage life sciences technology company focused on proteomics, aiming to make single-molecule protein sequencing widely accessible. It has developed its Platinum and higher-priced Platinum Pro next-generation protein sequencing instruments, sold with proprietary library preparation and sequencing kits plus Platinum Analysis Software.
The company targets research-use-only applications today, positioning its platform as a lower-cost, automated alternative and complement to legacy mass spectrometry and affinity-based methods. Management describes a large addressable market within a broader proteomics opportunity and plans to drive recurring consumables revenue from a growing installed base. A major roadmap milestone is the Proteus platform, expected to launch by the end of 2026 with much higher feature density and automation. Key risks include continued net losses and funding needs, potential delays or underperformance of Proteus, dependence on single-source contract manufacturers and semiconductor processes, evolving data, privacy and healthcare regulations, and governance factors such as controlled-company status, dual-class stock and the need to maintain Nasdaq listing.
Quantum-Si Incorporated reported wider full-year losses while preparing for its next-generation Proteus platform launch. For 2025, revenue was $2.4 million, with gross profit of $1.2 million and a gross margin of 47%. The company posted a 2025 net loss of $101.3 million, similar to the prior year, but reduced adjusted operating expenses to $86.3 million from $99.0 million.
In the fourth quarter of 2025, revenue was $0.5 million with a 27% gross margin and a net loss of $17.6 million. Management highlighted significant cost discipline and one-time litigation charges of $18.7 million during 2025. As of December 31, 2025, cash, cash equivalents and marketable securities totaled $215.8 million, which the company believes funds operations into the second quarter of 2028.
For 2026, Quantum-Si issued guidance for revenue of approximately $1.0 million, adjusted total operating expenses of $98.0 million or less, and total cash usage of $93.0 million or less. The company expects 2026 to be a transition year, intentionally moderating revenue as it embeds upgrade credits and placement programs to support a stronger commercial launch of the Proteus system, which has a list price of $425,000 and is targeted for launch by the end of 2026.
Quantum-Si Inc director Amir Jafri received a grant of 114,055 stock options on Class A Common Stock at an exercise price of $0.00 per share. The options vest in equal monthly installments beginning on March 31, 2026, subject to continued service. Following this, he directly holds 115,942 Class A shares.
Quantum-Si Incorporated (QSI) filed a Form 8-K to furnish materials from its Investor & Analyst Day held on November 19, 2025. The company used this event to present slides and a webcast replay that provide updates and summaries of its business, which are available in the Investors section of its website and attached as Exhibit 99.1. The company states that the information in this report, including Exhibit 99.1, is being furnished rather than filed under the Exchange Act and is not deemed incorporated into other securities filings unless specifically referenced.
Quantum-Si (QSI) reported Q3 2025 results with total revenue of $552 thousand, gross profit of $194 thousand, and a net loss of $35.7 million ($0.17 per share). Operating expenses included a $13.6 million lease termination expense and $1.8 million legal settlement expense (net of insurance), which weighed on results.
The company ended the quarter with $230.5 million in cash, cash equivalents and marketable securities. During 2025 it completed two registered direct offerings—$50.0 million gross each in January and July—resulting in net proceeds recorded of approximately $46.8 million and $46.7 million, respectively; July included pre-funded warrants exercised in full. A new $100.0 million at-the-market program with Leerink was established on September 26, 2025, with no sales during the quarter.
Other items: interest and dividend income was $2.6 million, and a $1.5 million gain from changes in warrant liabilities partially offset the operating loss. Class A shares outstanding were 195,520,747 as of September 30, 2025; Class B shares were 19,937,500. Management believes current liquidity will fund planned operations for at least twelve months.
Quantum-Si Incorporated furnished an Item 2.02 report announcing it issued a press release with results for the three and nine months ended September 30, 2025, along with a business update. The materials are furnished, not filed, under the Exchange Act.
Exhibits include 99.1 (press release dated November 5, 2025), 99.2 (use of non-GAAP financial measures), and 104 (cover page Inline XBRL).
Quantum‑Si (QSI) launched an at‑the‑market offering to sell up to $100,000,000 of Class A common stock under a Sales Agreement with Leerink Partners, which may act as sales agent on a best‑efforts basis or as principal. Sales may be made from time to time at market prices as defined in Rule 415(a)(4).
Leerink Partners will receive a commission of up to 3.0% of gross proceeds, and there is no escrow arrangement. The shares trade on Nasdaq as “QSI”; the last reported sale price was $2.18 on October 28, 2025.
Management intends to use any net proceeds for product development (including the Proteus platform), commercialization, manufacturing development, research and development, and other general corporate purposes such as working capital and capital expenditures. The company notes potential dilution to purchasers given variable sale prices and existing equity overhang. As context, shares outstanding were 164,357,534 as of June 30, 2025.
Quantum-Si (QSI) director and 10% owner Jonathan M. Rothberg reported the sale of 26,095 shares of Class A common stock on 10/16/2025 (transaction code S). The sale was executed pursuant to a Rule 10b5-1 trading plan established on September 13, 2024 and described as part of estate planning.
The filing states a weighted average price of $3.07 per share, with shares sold between $3.07 and $3.09. Following the transaction, beneficial ownership includes 2,568,443 Class A shares held directly and additional indirect holdings through various entities, including 1,904,866 Class A by NVR TR, LLC. Indirect holdings also include Class B common stock of 17,943,750 shares by 4C Holdings I, LLC and 1,993,750 shares by 4C Holdings V, LLC. The filing notes prior estate-planning distributions among affiliated trusts and that Dr. Rothberg disclaims beneficial ownership of shares held by his spouse and by 23rd Century Capital LLC.